Liver Fibrosis: Molecular Mechanisms, Potential Therapeutic Targets and Clinical Biomarkers 2nd Edition

Dear Colleagues,

Liver fibrosis is an important pathological condition that directly affects the prognosis of chronic liver diseases, including viral hepatitis and metabolic dysfunction-associated steatotic liver disease (MASLD). The mechanism of fibrosis formation has long been investigated. Recently, therapies targeting hepatic stellate cells (HSC) activation, fibrosis scar evolution, immunity, and cell death have been proposed. On the other hand, the development of non-invasive fibrosis biomarkers that do not require liver biopsy is underway. Serum markers such as FIB-4 and APRI, as well as US and MRI elastography, are gaining recognition. In this Special Issue, we focus on the study of cellular signals and receptors that are altered in liver fibrosis formation. Comprehensive studies summarizing potential therapeutic targets, reports of novel therapeutic targets, and discussions of the development of fibrosis biomarkers that could serve as indicators of fibrosis treatment are welcome.

Dr. Takefumi Kimura
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• liver fibrosis treatment
• therapeutic target biomarker
• hepatitis
• NAFLD
• NASH
• MAFLD
• HSC
• GPCR
• immunity cell death

• Liver Fibrosis: Molecular Mechanisms, Potential Therapeutic Targets and Clinical Biomarkers in Biomedicines (8 articles)